# AcK-Lock

### The Next Generation of Cancer Therapy



# Why AcK-Lock ?

### **Challenges for conventional cancer therapy**

- Targeting specific cancers
- Achieving complete cancer remission
- Reducing side effects and increasing safety

There is an urgent need for agents that address these challenges.



### What is **AcK-Lock**?



It's a simple chemical modification to selectively activate chemotherapeutic agents in cancer cells.



## Cancer cells: HDAC CTSL

HDAC (histone deacetylase) and CTSL (cathepsin L) are highly upregulated enzymes in many human cancer cells. While normal cells express these enzymes at basal level.





### How to use AcK-Lock?





Inactive in normal cells: "Safe-Locked"

AcK-Lock

**AcK-Lock conjugated Agent** 



### How does AcK-Lock work?





# Increased HDAC and CTSL in cancer cells lead to highly specific activation



#### Cancer cells: HDAC CTSL



What cancer can be targeted by AcK-Lock ?

- Colon
- Pancreas
- Breast and possibly more!
- Prostate
- Lung

# Our *in vitro* studies have shown that AcK-Lock works for a wide variety of cancers.



# **AcK-Lock** for selective cancer targeting



Signal in blue represents dead cells



### Other potential applications for AcK-Lock Technology

In addition to the therapeutic applications, AcK-Lock Technology can be used to develop imaging probes for selective cancer detection.





### **Additional Information**

Intellectual Property Status: International patents pending on compositions of matter and methods for cancer treatment and imaging.

<u>**Publication</u>:** A full scientific description of AcK-Lock Technology has been published in Nature Communications (doi:10.1038/ncomms3735).</u>

<u>Current Status in Development</u>: *In vivo* proof-of-concept data available, additional cytotoxic drugs being tested and evaluated using this system.



### Partnering

Our AcK-Lock platform has the potential to generate novel candidates for cancer therapy.

We are seeking strategic partners interested in accessing our AcK-Lock Technology for the treatment of cancer. We have a growing number of compounds available for partnering. We are also able to collaborate on the partners' proprietary compounds to generate novel AcK-Locked Agents.

A full scientific description of AcK-Lock Technology has been published in Nature Communications (doi:10.1038/ncomms3735).

